Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

High Dose Rituximab for Initial Treatment of Indolent B-Cell Lymphomas

This study has been completed.
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Genentech, Inc.
Information provided by (Responsible Party):
Jeremy Abramson, MD, Massachusetts General Hospital Identifier:
First received: May 6, 2009
Last updated: March 29, 2017
Last verified: March 2017
The purpose of this clinical trial is to see if increased doses of rituximab are safe and effective for the initial treatment of indolent B-cell lymphomas. Rituximab (Rituxan) is a type of drug called an "antibody" that specifically targets B-cell lymphoma cells, and is approved by the FDA for the treatment of indolent B-cell non-hodgkin lymphomas and certain other types of non-hodgkin lymphomas. Standard doses currently used may not be achieving maximal efficacy. Higher doses have been shown to be safe in other clinical trials, and may offer superior efficacy to the current standard dose. This trial also employs intermittent maintenance doses of rituximab at the standard dose, which has been shown to prolong remissions and survival in patients with relapsed indolent B-cell lymphomas. This trial is designed to show that higher dose rituximab plus maintenance rituximab can achieve similarly good results to chemotherapy approaches, but without chemotherapy-related toxicity.

Condition Intervention Phase
B-cell Lymphoma
Indolent B-cell Lymphoma
Drug: rituximab
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: Phase II Trial of Increased Dose Rituximab Plus Maintenance Rituximab for Initial Systemic Treatment of Indolent B-Cell Lymphomas

Resource links provided by NLM:

Further study details as provided by Massachusetts General Hospital:

Primary Outcome Measures:
  • Determine Complete Response Rate (CRR) of Increased Dose Rituximab in Indolent B-cell Lymphomas [ Time Frame: after a median number of 8 maintenance cycles ]

    CR requires all of the following:

    1. Regression to normal size on CT (≤ 1.5 cm in their greatest transverse diameter for nodes ≥ 1.5 cm before therapy). Previously involved nodes that were 1.1 to 1.5 cm in their greatest transverse diameter before treatment must have decreased to <1 cm in their greatest transverse diameter after treatment, or by more than 75% in the sum of the products of the greatest diameters (SPD).
    2. The spleen, if considered to be enlarged before therapy on the basis of a CT scan, must have regressed in size and must not be palpable on physical examination.
    3. If bone marrow is known to be involved at the beginning, then repeat biopsy documents clearance

Secondary Outcome Measures:
  • Overall Response Rate (ORR) [ Time Frame: after a median number of 8 maintenance cycles ]

    Complete Response (CR): see definition in primary outcome

    Partial Response (PR):

    1. ≥50% decrease in SPD of up to 6 largest dominant masses
    2. No new sites of disease or increase in the size of the other nodes, liver, or spleen.
    3. Splenic and hepatic nodules must regress by at least 50% in the SPD.

    Overall Response (OR) = CR + PR.

  • Progression-free Survival (PFS) [ Time Frame: 5 years ]

    Progressive Disease (PD) or Relapsed Disease (RD):

    1. Appearance of a new lesion(s) > 1.5 cm in any axis, ≥ 50% increase in SPD of more than one node, or ≥50% increase in longest diameter of a previously identified node > 1 cm in short axis.
    2. >50% increase from nadir in the SPD of any previous lesions PFS is number of participants who have not died or had PD or RD.

  • Incidence of Severity of Infusion Reactions, Infections and Neutropenia [ Time Frame: 24 months ]
    Toxicity grades: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening

Enrollment: 40
Actual Study Start Date: July 2009
Study Completion Date: August 2015
Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
single-arm, open-label, interventional
Drug: rituximab
Increased dose (750 mg/m2) intravenously for 4 weekly doses followed by maintenance dosing once every three months for up to 2 years. Maintenance dose is standard (375 mg/m2).
Other Name: Rituxan

Detailed Description:
  • All participants will receive increased-dose rituximab through a vein in the arm once a week for 4 weeks (on Days 1, 8, 15, and 22 of the initial 28-day study cycle). This first cycle of study treatment is called the Induction Phase. If the participant responds well to the Induction Phase, they then may continue to the Maintenance Therapy Phase, where they will receive a lower dose of rituximab once every three months for up to 2 years.
  • During the Induction Phase, the following procedures will take place before the participant receives each dose of rituximab: medical review, physical exam, performance status, and ECG. Blood tests will be drawn about 30-60 minutes after the first dose of rituximab on Day 1. Samples will be drawn immediately before each dose and again 30-60 minutes after each dose on Days 1, 8, 15 and 22.
  • During the Maintenance Therapy Phase, the following procedures will take place before the participant receives each dose of rituximab: medical review, physical exam, performance status, ECG, blood tests and response assessments by CT scan.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Indolent B-Cell NHL of the following histologies:

    1. Follicular lymphoma (grades 1-3A);
    2. marginal zone lymphoma (extranodal, nodal or splenic):

      • Extranodal marginal zone lymphomas (MALT lymphomas) may not be candidates for cure with antibiotics or local radiotherapy. Patients who have failed antibiotics or local therapy are eligible for the protocol as long as they have measurable disease and are naive to chemotherapy and monoclonal antibody;
      • splenic marginal zone lymphoma patients may have received prior splenectomy as long as they have measureable disease and are naive to chemotherapy and monoclonal antibody therapy;
    3. Small lymphocytic lymphoma (must have less than 5000 circulating clonal B-lymphocytes);
    4. Indolent CD20+ B-cell lymphoma not otherwise specified with CD20+ expression
  • Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as 20mm or greater with conventional techniques or as 10mm or greater with spiral CT scan
  • No previous chemotherapy, antibody therapy or radioimmunotherapy for NHL. Patients previously treated with external bean radiation alone, surgery, or with antibiotics are eligible
  • 18 years of age or older
  • Life expectancy of greater than 3 months
  • ECOG performance status of 2 or less
  • Adequate bone marrow function
  • Use of adequate contraception

Exclusion Criteria:

  • Prior chemotherapy, monoclonal antibody therapy or radioimmunotherapy for lymphoma
  • Receiving any other investigational agent
  • Known brain metastases
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to rituximab
  • HIV positivity
  • Active hepatitis B infection
  • Candidate for curative radiotherapy, unless radiation therapy is considered too toxic (as in abdominal disease), or is refused by the patient
  • NYHA Classification III or IV disease
  • Uncontrolled intercurrent illness including, but not limited to ongoing or active infection that is not optimally treated with antibiotics, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnant women
  • Individuals with a history of a different malignancy except for the following circumstances:

    1. disease-free for at least 1 year and are deemed by the investigator to be at low risk for recurrence of that malignancy;
    2. localized prostate cancer, prostate cancer with elevated PSA but no measurable disease on CT scans or bone scan, cervical cancer in situ; and
    3. non-melanoma skin cancers
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00895661

United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Massachusetts General Hospital
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Genentech, Inc.
Principal Investigator: Jeremy Abramson, MD Massachusetts General Hospital
  More Information

Responsible Party: Jeremy Abramson, MD, Director, Lymphoma Program, Massachusetts General Hospital Identifier: NCT00895661     History of Changes
Other Study ID Numbers: 09-054
Study First Received: May 6, 2009
Results First Received: March 29, 2017
Last Updated: March 29, 2017

Keywords provided by Massachusetts General Hospital:

Additional relevant MeSH terms:
Lymphoma, B-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents processed this record on May 24, 2017